Ascendis Pharma A/S Announces Participation in Two Upcoming Investor Conferences
October 31, 2017 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
September 27, 2017 00:16 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
September 26, 2017 16:17 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public...
Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH
September 26, 2017 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
September 05, 2017 16:25 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
August 18, 2017 07:00 ET
|
Ascendis Pharma A/S
- Clinical Pipeline Expands to Include TransCon PTH while Phase 3 Program for TransCon Growth Hormone Advances - - Conference Call Today at 8:00 a.m. Eastern Time - COPENHAGEN, Denmark, Aug. ...
Ascendis Pharma A/S Announces Upcoming Investor Presentations
August 08, 2017 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Second Quarter 2017 Financial Results Conference Call on August 18
August 03, 2017 16:30 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...